This privacy notice tells you what to expect IQVIA Ltd (“us/we/our”) to do with your personal information in the context of the Digital Clinical Excellence (DiCE) Study.

• Contact details
• What information we collect, use, and why
• Lawful bases and data protection rights
• Where we get personal information from
• How long we keep information

Contact details

Email :
DiCE_RWE_Study@iqvia.com

What information we collect, use, and why

We collect or use the following types of personal information for research or archiving purposes:

• Medical data namely:
  • Age and sex
  • Weight, height, BMI, and blood pressure
  • Medical conditions and medications
  • Treatment details and outcomes

We also collect or use the following special category information for research or archiving purposes. This information is subject to additional protection due to its sensitive nature:

• Racial or ethnic origin
• Health information

How is my data used?

Your data is combined with data from other patients. Researchers analyse this to understand trends and outcomes. Results are reported as group statistics, never as individual data. Findings will be published to help improve future care.

How is my privacy protected?

• Data is pseudonymised before being shared
• Transferred securely and stored on protected IQVIA servers
• Access is limited to authorised researchers
• IQVIA employs strict data security measures and is ISO 27001 certified
• Data is used only for this study and securely deleted after completion

The research study

A consortium of independent digital health providers within the Digital Clinical Excellence (DiCE) UK network is conducting a retrospective, multi-provider RWE study with IQVIA to explore the clinical effectiveness and governance of digitally enabled weight management interventions, including GLP-1 medications, delivered via regulated digital platforms.

The study aims to generate high-quality, real-world data to support the clinical and systemic value of digital-first, wrap-around care models in obesity management.

Specific objectives include:

- Characterising patient demographics and clinical characteristics across digital obesity services

- Assessing treatment effectiveness, adherence and safety across diverse populations

- Documenting the robustness of clinical governance and prescribing safeguards within digital pathways If data availability permits, exploratory objectives may include assessing indicators of socio-economic impact, healthcare resource utilisation and potential effects of anti-obesity medications on comorbidities.

Insights from this work will contribute to the development of best practices for digital obesity care and the broader evaluation of digital therapeutics in routine clinical practice. Study outcomes are anticipated for dissemination in Q1-Q2 2026.

Why it is relevant

The UK weight management market is experiencing rapid expansion, with over 2 million GLP-1 packs dispensed by private digital healthcare providers in July 2025 alone. This surge, largely driven by digital-first models, is transforming access to obesity treatments and drawing increased regulatory attention. The DiCE study aims to address a critical evidence gap by examining real-world outcomes and governance in this evolving landscape - an urgent public health priority.

Our lawful bases for the collection and use of your data

Our lawful bases for processing personal information for the DiCE study are:

• Legitimate interests – we’re collecting or using your information because it benefits you, our organisation or someone else, without causing an undue risk of harm to anyone. Our legitimate interests are to assess, through this study, the private prescription market providing anti-obesity medication to patients in the UK. The private market is by far the most significant distributor of these medications, far outstripping that of the NHS. Furthermore, this data is currently not available for research use and is presently a black box when it comes to whether the providers comply with UK national guidelines and the outcomes that patients are experiencing. This research can drive health policy changes or adoption of new guidelines for healthcare providers, thus leading to improved outcomes for patients. Population-based medical research studies using patient data aims to advance medical knowledge and understanding in both disease management and in public health, for prescribers, payers and key opinion leaders within the medical communities as well as help patients better understand their medical conditions. For more information about our legitimate assessment of our legitimate interests used to determine our lawful basis for processing, you can contact us using the contact details set out above.
• Processing is necessary for research purposes under Art 9(2) UK GDPR and in accordance with Article 89(1) of UK GDPR and subject to appropriate privacy protective safeguards.

Your rights

• Access - You have the right to request a copy of your personal information.
• Rectification - You have the right to request correction of your information or deletion of personal information you think is inaccurate or incomplete.
• Erasure - You have the right to request deletion of your personal information.
• Restrict processing - You have the right to request limits on how we process your personal information.
• Object to processing - You have the right to object to any processing of your personal data.
• Your right to data portability - You have the right to request transfer of the personal information you gave us to another organisation, or to you.
• Your right to withdraw consent – When we use consent as our lawful basis you have the right to withdraw your consent at any time using the contact information in this notice.

To exercise any of these rights or for questions about the way in which IQVIA processes your personal information, please contact us using the contact details at the top of this privacy notice or you can send an email to our Data Protection Officer at eu.dpo@iqvia.com.

Where we get personal information from

• Digital health providers who are part of the study within the Digital Clinical Excellence (DiCE) UK network.

Who we share information with

Data processors

Third-party vendors to support data standardisation and other aspects of the research.

How long we keep information

This data will be collected one time for the purpose of this study. It will be retained for the duration of the study and to support publication after the study concludes. After the final publication is accepted and the publication date is agreed, the data will be securely held for 12 months to allow for potential audit, after which it will be destroyed.